These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29239950)

  • 21. US Food and Drug Administration Clinical Investigator Inspections.
    Buchmeier AD
    Semin Oncol Nurs; 2020 Apr; 36(2):151000. PubMed ID: 32253049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters.
    Bramstedt KA
    Ther Innov Regul Sci; 2021 Jan; 55(1):239-244. PubMed ID: 33001378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
    Sams L; Slagle AF; Symonds T; Antonova J; Globe D
    Value Health; 2023 Dec; 26(12):1675-1680. PubMed ID: 37748736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
    Chatterjee S; Patel HK; Sansgiry SS
    Pharm Pract (Granada); 2012 Oct; 10(4):194-8. PubMed ID: 24155837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022.
    Dmour I
    J Pharm Innov; 2022 Nov; ():1-15. PubMed ID: 36407089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009.
    Morgan-Linnell SK; Stewart DJ; Kurzrock R
    Clin Cancer Res; 2014 Jul; 20(13):3364-70. PubMed ID: 24737548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
    Nguyen D; Seoane-Vazquez E; Rodriguez-Monguio R; Montagne M
    BMC Health Serv Res; 2013 Jan; 13():27. PubMed ID: 23339419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An audit of US FDA warning letters issued to sponsors, institutional review boards and investigators over a six-year period.
    Saxena U; Bose D; Saha S; Gogtay NJ; Thatte UM
    Indian J Med Ethics; 2022; VII(2):108-113. PubMed ID: 35765256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H
    Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
    Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
    Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
    Mohite N; Funtanilla V; Muzumdar J; Park T
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ; Bliss SK
    Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical device warning letter pilot. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Mar; 64(44):11018-23. PubMed ID: 10557622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP; Sheikhan NY; Pinto A; Sheikhan T; Witek TJ
    Pharmaceut Med; 2021 Jan; 35(1):31-38. PubMed ID: 33453042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical device warning letter draft pilot; availability--FDA. Notice.
    Fed Regist; 1998 Aug; 63(166):45821-5. PubMed ID: 10182695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants.
    Chahal HS; Mukherjee S; Sigelman DW; Temple R
    JAMA Intern Med; 2021 Apr; 181(4):522-529. PubMed ID: 33587091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Data Integrity: History, Issues, and Remediation of Issues.
    Rattan AK
    PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study.
    Lurie P; Chahal HS; Sigelman DW; Stacy S; Sclar J; Ddamulira B
    BMJ; 2015 Jun; 350():h2758. PubMed ID: 26063327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.